Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Fox

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Expert Opinion on Pharmacotherapy|May 31, 2006
Selective and specific I(f) inhibition: new perspectives for the treatment of stable anginaKim Fox
Nature Reviews. Cardiology|May 27, 2016
Heart rate reduction in coronary artery disease and heart failureRoberto Ferrari, Kim Fox
Drugs|March 12, 2009
Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' storyRoberto Ferrari, Kim Fox
Advances in Cardiology|August 29, 2006
Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowingGaetano Antonio Lanza, Kim Fox, Filippo Crea
European Heart Journal|August 15, 2006
Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?Kim Fox, Roberto Ferrari, Salim Yusuf, et al.
Circulation|February 20, 2003
Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trialJeffrey S Borer, Kim Fox, Patrice Jaillon, et al.
American Heart Journal|October 31, 2006
Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) studyKim Fox, Roberto Ferrari, Michal Tendera, et al.
Lancet (London, England)|September 2, 2008
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trialKim Fox, Ian Ford, P Gabriel Steg, et al.
European Heart Journal|September 12, 2018
Can we remove scar and fibrosis from adult human myocardium?Ali Vazir, Kim Fox, Joseph Westaby, et al.
European Heart Journal|October 11, 2005
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable anginaJean-Claude Tardif, Ian Ford, Michal Tendera, et al.
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Expert Opinion on Pharmacotherapy|May 31, 2006
Selective and specific I(f) inhibition: new perspectives for the treatment of stable anginaKim Fox
Nature Reviews. Cardiology|May 27, 2016
Heart rate reduction in coronary artery disease and heart failureRoberto Ferrari, Kim Fox
Drugs|March 12, 2009
Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' storyRoberto Ferrari, Kim Fox
Advances in Cardiology|August 29, 2006
Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowingGaetano Antonio Lanza, Kim Fox, Filippo Crea
European Heart Journal|August 15, 2006
Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?Kim Fox, Roberto Ferrari, Salim Yusuf, et al.
Circulation|February 20, 2003
Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trialJeffrey S Borer, Kim Fox, Patrice Jaillon, et al.
American Heart Journal|October 31, 2006
Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) studyKim Fox, Roberto Ferrari, Michal Tendera, et al.
Lancet (London, England)|September 2, 2008
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trialKim Fox, Ian Ford, P Gabriel Steg, et al.
European Heart Journal|September 12, 2018
Can we remove scar and fibrosis from adult human myocardium?Ali Vazir, Kim Fox, Joseph Westaby, et al.
European Heart Journal|October 11, 2005
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable anginaJean-Claude Tardif, Ian Ford, Michal Tendera, et al.
Pageof 7